MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

339,87

18-февраля-25 16:45:00

15 мин. задержка

Акции

+2,67

+0,79%

Сегодняшний диапазон

334,50 - 341,02

ISIN

N/A

Источник

NASDAQ

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Statement on the Passing of Dr. Stephen Harrison

24 апр 2024 16:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

23 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

09 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 мар 2024 23:58:56 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Proposed Public Offering

18 мар 2024 16:04:05 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 мар 2024 16:15:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

05 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

28 фев 2024 07:01:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

28 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

08 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

29 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.